natgillin/translations-raw huggingface dataset:
When considering concomitant administration of ketoconazole or other potent CYP3A4 inhibitors with aripiprazole, potential benefits should outweigh the potential risks to the patient. 
Pri odločanju o sočasni uporabi ketokonazola ali drugih močnih zaviralcev CYP3A4 z aripiprazolom morajo morebitne koristi odtehtati morebitna tveganja za bolnika.
What you need to know before you are given Abilify Maintena Do not use Abilify Maintena: 
Kaj morate vedeti, preden boste doblili zdravilo Abilify Maintena Ne uporabljajte zdravila Abilify Maintena:
MM/YYYY 
MM/LLL
Oral aripiprazole 10-30 mg/day (n = 266) 
Peroralni aripiprazol 10-30 mg/dan (n = 266)
In the placebo group 39.6 % of the patients had progressed to impending relapse, whilst in the Abilify Maintena group impending relapse occurred in 10 % of the patients; thus patients in the placebo group had a 5.03-fold greater risk of experiencing impending relapse. 
Iz skupine s placebom je 39,6 % bolnikov napredovalo v skupino z znaki bližnjega relapsa, medtem ko so se v skupini z zdravilom Abilify Maintena znaki bližnjega relapsa pojavili pri 10 % bolnikov, zato je pri bolnikih iz skupine s placebom obstajalo 5,03-krat večje tveganje za znake bližnjega relapsa.
When seen, it is usually in those with significant risk factors such as history of diabetes, thyroid disorder or pituitary adenoma. 
Če se pojavi, se ponavadi pojavi pri bolnikih s pomembnimi dejavniki tveganja, npr. anamnezo sladkorne bolezni, motnjami ščitnice ali adenomom hipofize.
Aripiprazole has minor to moderate influence on the ability to drive and use machines due to potential nervous system and visual effects, such as sedation, somnolence, syncope, vision blurred, diplopia (see section 4.8). 
Aripiprazol ima blag do zmeren vpliv na sposobnost vožnje in upravljanje s stroji zaradi morebitnega vpliva na živčni sistem in vid, kot je sedacija, zaspanost, sinkopa, zamegljen vid in diplopija (glejte poglavje 4.8).
Similarly, for dehydro-aripiprazole the geometric means of Cmax and AUC after carbamazepine co-administration were 69 % and 71 % lower, respectively, than those following treatment with oral aripiprazole alone. 
Podobno je bila po sočasni uporabi karbamazepina geometrična sredina Cmax dehidroaripiprazola za 69 % nižja, njegov AUC pa za 71 % nižji kot po zdravljenju s samo peroralnim aripiprazolom.
• severe liver problems. 
• hude težave z jetri.
b: Only patients having both baseline and at least one post baseline were included. 
b: vključeni so bili samo bolniki, za katere je bila znana izhodiščna vrednost in vsaj ena nadaljnja vrednost.
A simulation of dose dumping showed that the predicted median aripiprazole concentration reaches a peak of 4,500 ng/ml or approximately 9 times the upper therapeutic range. 
Simulacija sprostitve celotnega odmerka hkrati je pokazala, da predvidena mediana koncentracije aripiprazola doseže najvišjo vrednost 4.500 ng/ml ali približno 9-kratno zgornjo mejo terapevtskega območja.
The reconstituted product suspension should appear to be a uniform, homogeneous suspension that is opaque and milky-white in colour. 
Rekonstituirano zdravilo mora biti na videz homogena, neprosojna in mlečno bela suspenzija.
New-born infants exposed to antipsychotics (including aripiprazole) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. 
Pri novorojenčkih, ki so bili v tretjem trimesečju nosečnosti izpostavljeni antipsihotikom (vključno z aripiprazolom), obstaja tveganje za pojav neželenih učinkov, vključno z ekstrapiramidnimi in/ali odtegnitvenimi simptomi, ki se lahko razlikujejo glede na jakost in čas trajanja po porodu.
Needle cap d) Then pull needle-cap straight up. 
Pokrovček igle d) Nato pokrovček igle povlecite naravnost navzgor.
Caution should be taken when treating patients at higher risk, and a lower starting dose should be considered (e.g., elderly or debilitated patients; see section 4.2). 
zato je treba razmisliti o nižjem začetnem odmerku (npr. pri starejših ali oslabljenih bolnikih; glejte poglavje 4.2).
- higher amounts of gamma-glutamyl transferase 
- zvišane količine gama-glutamil-transferaze,
Solvent for Abilify Maintena Water for injections 
Vehikel za zdravilo Abilify Maintena voda za injekcije
It has been proposed that aripiprazole's efficacy in schizophrenia is mediated through a combination of partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism at serotonin 5-HT2A receptors. 
Učinkovitost aripiprazola pri shizofreniji je domnevno posledica kombinacije delnega agonizma na dopaminskih receptorjih D2 in serotoninskih receptorjih 5-HT1A ter antagonizma na serotoninskih receptorjih 5-HT2A.
g) Slowly withdraw the recommended volume from the vial into the luer lock syringe to allow for injection. 
g) Priporočeno količino izvlecite iz viale v injekcijsko brizgo z nastavkom Luer Lock, da omogočite injiciranje.
Twist + Pull Off 
Obrnite + snemite
Figure 1 Kaplan-Meier Product Limit Plot for Time to Exacerbation of Psychotic Symptoms/Impending Relapse 
Slika 1 Analiza funkcije preživetja Kaplan-Meier za čas do poslabšanja psihotičnih simptomov/pojava znakov bližnjega relapsa
Discard vial, adapter, syringe, needles, unused suspension and water for injections appropriately. 
Vialo, nastavek, injekcijsko brizgo, igle, neporabljeno suspenzijo ali vodo za injiciranje ustrezno zavrzite.
Aripiprazole should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischaemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medicinal products) or hypertension, including accelerated or malignant. 
Aripiprazol je treba previdno uporabljati pri bolnikih z znano srčnožilno boleznijo (anamnezo srčnega infarkta ali ishemično boleznijo srca, srčnim popuščanjem ali prevodnimi motnjami), cerebrovaskularno boleznijo ali stanji, ki povzročajo nagnjenost k hipotenziji (dehidracija, hipovolemija, zdravljenje z antihipertenzivi) ali hipertenziji, vključno s pospešeno in maligno hipertenzijo.
• pain at the injection site, hardening of the skin at the injection site 
• bolečina na mestu injiciranja, otrdelost kože na mestu injiciranja,
Multipack Bundle pack of 3 single packs. 
Skupno pakiranje 3 posameznih pakiranj.
f) Place and hold the vial of the reconstituted suspension on a hard surface. 
f) Vialo z rekonstituirano suspenzijo položimo in pridržimo ob trdi površini.
Cases of serotonin syndrome have been reported in patients taking aripiprazole, and possible signs and symptoms for this condition can occur especially in cases of concomitant use with other serotonergic medicinal products, such as SSRI/SNRI, or with medicinal products that are known to increase aripiprazole concentrations (see section 4.8). 
Pri bolnikih, ki jemljejo aripiprazol, so poročali o primerih serotoninskega sindroma, morebitni znaki in simptomi tega stanja pa se lahko pojavijo zlasti ob sočasnem jemanju z drugimi serotonergičnimi zdravili, kot so selektivni zaviralci prevzema serotonina (SSRI) selektivni zaviralci prevzema noradrenalina (SNRI), ali drugimi zdravili, ki dokazano zvišujejo koncentracijo aripiprazola (glejte poglavje 4.8).
The occurrence of suicidal behaviour is inherent in psychotic illnesses, and in some cases has been reported early after initiation or switch of antipsychotic treatment, including treatment with aripiprazole (see section 4.8). 
S psihozami je povezan tudi pojav samomorilnega vedenja, o katerem so v nekaterih primerih poročali kmalu po začetku antipsihotičnega zdravljenja, vključno z zdravljenjem z aripiprazolom (glejte poglavje 4.8).
• aggression 
• agresija,
Multipack: Three single packages, each containing: 
Skupno pakiranje: tri enojna pakiranja, vsako pakiranje vsebuje naslednje: Ena viala s praškom
Aripiprazole exhibits high binding affinity in vitro for dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors and has moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha-1 adrenergic, and histamine H1 receptors. 
Aripiprazol je imel v raziskavi in vitro veliko vezavno afiniteto za dopaminske receptorje D2 in D3 in za serotoninske receptorje 5-HT1A in 5-HT2A ter zmerno afiniteto za dopaminske receptorje D4, serotoninske receptorje 5-HT2C in 5-HT7, adrenergične receptorje alfa-1 in histaminske receptorje H1.
f) Slowly inject into the gluteal or deltoid muscle. 
f) Počasi injicirajte v glutealno ali deltoidno mišico.
Vertically shake the syringe vigorously for 20 seconds until medicine is uniformly milky-white and use immediately. 
Injekcijsko brizgo 20 sekund navpično močno stresajte, dokler zdravilo ni homogene, mlečno bele barve, in ga uporabite takoj za tem.
• an acutely agitated state or a severely psychotic state 
• akutno agitirano stanje ali hudo psihotično stanje,
Your doctor will decide on the dose of Abilify Maintena that is right for you. 
Zdravnik bo določil, kolikšen odmerek zdravila Abilify Maintena je za vas ustrezen.
• acute confusion, seizures (epilepsy), coma, a combination of fever, faster breathing, sweating, 
• akutno zmedenost, krče (epilepsijo), komo, kombinacijo povišane telesne temperature, hitrega dihanja, znojenja;
Full instructions for use and handling of Abilify Maintena are provided in the package leaflet (information intended for healthcare professionals). 
Za celotna navodila o uporabi in ravnanju z zdravilom Abilify Maintena glejte navodila za uporabo (informacije za zdravstvene delavce).
Patients treated with aripiprazole should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control (see section 4.8). 
Bolnike, ki prejemajo aripiprazol, je treba opazovati za znaki in simptomi hiperglikemije (npr. polidipsije, poliurije, polifagije in šibkosti), bolnike, ki imajo sladkorno bolezen ali dejavnike tveganja zanjo, pa redno spremljati, da bi odkrili poslabšanje uravnavanja glukoze (glejte poglavje 4.8).
There was a statistically significant treatment difference in favour of Abilify Maintena 400 mg/300 mg compared to placebo at week 10 (+7.1, p < 0.0001, 95 % CI: 4.1, 10.1 using an ANCOVA model (LOCF)). 
Abilify Maintena 400 mg/300 mg v primerjavi s placebom v 10. tednu (+7,1, p < 0,0001, 95-odstotni IZ: 4,1, 10,1 z modelom ANCOVA (LOCF)).
a: Negative change in score indicates improvement. 
Ni na voljo a: negativna sprememba ocene kaže na izboljšanje bolnikovega stanja.
g) Visually inspect the reconstituted suspension for particulate matter and discolouration prior to administration. 
g) Rekonstituirano suspenzijo pred dajanjem preglejte za delci in obarvanjem.
Based on results from trials with oral administration of aripiprazole, aripiprazole is widely distributed throughout the body with an apparent volume of distribution of 4.9 l/kg, indicating extensive extravascular distribution. 
Na podlagi preskušanj s peroralnim dajanjem aripiprazola se aripiprazol široko porazdeli po telesu in ima navidezni volumen porazdelitve 4,9 l/kg, kar kaže na izdatno zunajžilno distribucijo.
An additional finding was cholelithiasis as a consequence of precipitation of sulphate conjugates of hydroxy-metabolites of aripiprazole in the bile of monkeys after repeated oral dosing at 25 to 125 mg/kg/day or approximately16 to 81 times the maximum recommended human dose based on mg/m2. 
Dodaten izsledek je bila holelitiaza zaradi precipitacije sulfatnih konjugatov hidroksipresnovkov aripiprazola v žolču opic po ponavljajočem odmerjanju od 25 do 125 mg/kg/dan ali približno 16- do 81-kratni največji priporočeni odmerek za človeka glede na mg/m2.
This trial consisted of a screening phase and 3 treatment phases: Conversion Phase, Oral Stabilisation Phase, and Double-blind, Active-controlled Phase. 
To preskušanje so sestavljale presejalna faza in tri faze zdravljenja: faza prehoda, faza peroralne stabilizacije in dvojno slepa s placebom nadzorovana faza.
Other medicines and Abilify Maintena 
Druga zdravila in zdravilo Abilify Maintena
• thoughts about suicide 
• samomorilne misli,
Your doctor or nurse will make it into a suspension that will be given as an injection using the vial of solvent for Abilify Maintena that comes as a clear solution in a clear glass vial. 
Zdravnik ali medicinska sestra bo pripravil/-a suspenzijo, ki se injicira z vialo z vehiklom zdravila Abilify Maintena, ki je na voljo kot bistra raztopina v viali iz prozornega stekla.
No interaction studies have been performed with Abilify Maintena. 
Študij medsebojnega delovanja z zdravilom Abilify Maintena niso izvedli.
The reconstituted medicine is a white to off-white, fluid suspension. 
Rekonstituirano zdravilo je bela do belkasta tekoča suspenzija.
• decreased or increased blood levels of the hormone prolactin 
• znižane ali zvišane vrednosti hormona prolaktina v krvi,
The concomitant use of CYP3A4 inducers with Abilify Maintena should be avoided because the blood levels of aripiprazole are decreased and may be below the effective levels. 
Sočasni uporabi močnih induktorjev CYP3A4 z zdravilom Abilify Maintena se je treba izogibati, saj se raven aripiprazola v krvi zniža in lahko pade pod učinkovito raven.
When compared to studies where Abilify Maintena was injected in the gluteal muscle, repeated occurrence of injection site pain was more frequent in the deltoid muscle. 
V primerjavi s študijami, v katerih je bilo zdravilo Abilify Maintena injicirano v glutealno mišico, je bila večkratna pojavnost bolečine na mestu injiciranja pogostejša pri injiciranju v deltoidno mišico.
• decreased or increased appetite 
• povečan ali zmanjšan tek,
b) Select one of the following hypodermic safety needles depending on the injection site and patient's weight and attach the needle to the luer lock syringe containing the suspension for injection. 
b) Glede na mesto injiciranja in telesno maso bolnika izberite eno od spodnjih varnostnih podkožnih igel in iglo pritrdite na injekcijsko brizgo z nastavkom Luer Lock, ki vsebuje suspenzijo za injiciranje.
• during tests your doctor may find higher amounts alkaline phosphatase fluctuating results during tests to measure glucose in your blood 
• med testiranji lahko zdravnik ugotovi: zvišane količine alkalne fosfataze, nihanje med merjenji glukoze v krvi.
• if you have symptoms such as swelling, pain, and redness in the leg, because this may mean you have a blood clot, which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing. 
• simptome, kot so otekanje, bolečina in pordelost kože na nogah, saj so lahko ti znak prisotnosti krvnih strdkov, ki lahko po krvnih žilah potujejo v pljuča in povzročijo bolečine v prsnem košu in težko dihanje.
After administration of multiple dose of 400 mg or 300 mg of Abilify Maintena, the mean aripiprazole terminal elimination half-life is respectively 46.5 and 29.9 days presumably due to absorption ratelimited kinetics. 
Izločanje Po večkratnem odmerjanju zdravila Abilify Maintena 400 mg ali 300 mg je srednji razpolovni čas izločanja aripiprazola približno 46,5 dneva in 29,9 dneva, domnevno zaradi kinetike, omejene s hitrostjo absorpcije.
Injection site pain (incidence 5.1 %), had a median onset on day 2 after the injection and a median duration of 4 days. 
Mediana časa do začetka bolečin na mestu injiciranja (pojavnost 5,1 %) je nastopila 2. dan po injiciranju, mediana trajanja pa je znašala 4 dni.
Based on population pharmacokinetic evaluation of Abilify Maintena, the total body clearance of aripiprazole was 3.71 L/h in extensive metabolisers of CYP2D6 and approximately 1.88 L/h (approximately 50 % lower) in poor metabolisers of CYP2D6 (for dose recommendation, see section 4.2). 
Na podlagi populacijske farmakokinetične analize zdravila Abilify Maintena je bil celotni telesni očistek aripiprazola 3,71 l/h pri osebah, ki dobro presnavljajo s CYP2D6 in približno 1,88 l/h (približno 50 % nižje) pri osebah, ki slabo presnavljajo sCYP2D6 (za priporočene odmerke glejte poglavje 4.2).
b Difference (Abilify Maintena minus placebo) in least squares mean change from baseline. 
b Sprememba (Abilify Maintena minus placebo) povprečja najmanjših kvadratov od izhodišča.
Intramuscular use only 
samo za intramuskularno uporabo
Additionally, it is known that the use of aripiprazole is associated with other ADR that may predispose to falls, such as somnolence, sedation, dizziness or hypotension. 
Poleg tega je znano, da je uporaba aripiprazola povezana z drugimi neželenimi učinki, kot so somnolenca, sedacija, omotica ali hipotenzija, ki lahko povzročijo padce.
Add 1.9 ml solvent to reconstitute the powder. 
Dodajte 1,9 ml vehikla, da rekonstituirate prašek.
300 mg vial: 
300 mg viala:
The estimated proportion of patients experiencing impending relapse by end of Week 26 for Abilify Maintena was 7.12 %, which was statistically significantly lower than in aripiprazole Long-Acting Injectable 50 mg/25 mg (21.80 %; p = 0.0006). 
Ocenjeno razmerje bolnikov, pri katerih se do konca 26. tedna pojavijo znaki bližnjega relapsa bolezni, je pri zdravilu Abilify Maintena znašalo 7,12 %, kar je bilo statistično bistveno nižje kot pri dolgodelujočem parantertalnem aripiprazolu 50 mg/25 mg (21,80 %; p = 0,0006).
The efficacy of Abilify Maintena in acutely relapsed adult patients with schizophrenia was established in a short-term (12-week), randomised, double-blind, placebo-controlled trial (n = 339). 
Akutno zdravljenje shizofrenije pri odraslih bolnikih Učinkovitost zdravila Abilify Maintena pri odraslih bolnikih z akutnim relapsom shizofrenije so ugotavljali v kratkotrajnem (12-tedenskem), randomiziranem, dvojno slepem, s placebom nadzorovanem preskušanju (n = 339).
If you are receiving Abilify Maintena, your doctor will discuss with you whether you should breastfeed considering the benefit to you of your therapy and the benefit to your baby of breast-feeding. 
Če prejemate zdravilo Abilify Maintena, vam bo zdravnik pomagal pri odločitvi glede dojenja z upoštevanjem prednosti dojenja za otroka in prednosti zdravljenja za vas.
The front chamber between front stopper and middle stopper contains the powder and the rear chamber between middle stopper and end stopper the solvent. 
Sprednja komora med sprednjim in srednjim zamaškom vsebuje prašek, zadnja komora med srednjim in končnim zamaškom pa vehikel.
Single pack 
Skupno pakiranje
• increased blood fats such as high cholesterol, high triglycerides and also low level of cholesterol and low level of triglycerides 
• povišane količine maščob v krvi, kot so holesterol, visoke vrednosti trigliceridov in nizke vrednosti holesterola in trigliceridov,
• heart problems including torsades de pointes, stopping of the heart, irregularities in heart rhythm that may be due to abnormal nerve impulses in the heart, abnormal readings during heart examination (ECG) QT prolongation 
• težave s srcem, vključno s »torsades de pointes«, zastoj srca, nepravilnosti srčnega ritma, ki so lahko posledica normalnih živčnih impulzov v srcu, nenormalni odčitki pri srčnem pregledu
Contents of the pack and other information What Abilify Maintena contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Abilify Maintena
Renal impairment No dosage adjustment is required for patients with renal impairment (see section 5.2). 
Ledvična okvara Pri bolnikih z ledvično okvaro odmerka ni treba prilagajati (glejte poglavje 5.2).
Do not use this medicine after the expiry date which is stated on the carton and the pre-filled syringe. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in napolnjeni injekcijski brizgi.
Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). 
Klinični znaki MNS so hiperpireksija, mišična rigidnost, spremenjeno duševno stanje in znaki avtonomne labilnosti (nereden srčni utrip ali krvni tlak, tahikardija, čezmerno potenje in motnje srčnega ritma).
It should only be administered by a healthcare professional. 
Zdravilo sme dajati samo zdravstveni delavec.
A small amount of excess product will remain in the vial. 
Po tem bo v viali ostala majhna količina preostalega vehikla.
Taking into account the PRAC Assessment Report on the PSUR(s) for aripiprazole, the scientific conclusions of CHMP are as follows: 
Upoštevajoč poročilo Odbora za oceno tveganja na področju farmakovigilance (PRAC) o oceni rednih posodobljenih poročil o varnosti zdravila (PSUR) za aripiprazol je Odbor za zdravila za uporabo v humani medicini (CHMP) sprejel naslednje znanstvene zaključke:
Upon discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of aripiprazole should be increased to the dose prior to the initiation of the concomitant therapy. 
Po prekinitvi uporabe zaviralca CYP2D6 ali CYP3A4 je treba odmerjanje aripiprazola povečati na raven, kakršna je bila pred uvedbo sočasne terapije.
400 mg vial: 
400 mg viala:
Ensure the needle is firmly seated on the needle protection device with a push and clockwise twist and then pull the needle cap straight away from the needle. 
Preverite, ali je igla čvrsto pritrjena na varnostnem pripomočku, tako da jo pritisnete in obrnete v desno, nato pa potegnite pokrovček naravnost stran od igle.
In case of adverse reactions despite dose adjustments of Abilify Maintena, the necessity of concomitant use of CYP2D6 or CYP3A4 inhibitor should be reassessed. 
Če se kljub prilagoditvi odmerkov zdravila Abilify Maintena pojavijo neželeni učinki, je treba ponovno oceniti potrebo sočasnega jemanja zaviralcev CYP2D6 ali zaviralcev CYP3A4.
One vial of 2 ml solvent 
Ena viala z 2 ml vehikla
After reconstitution each ml of suspension contains 200 mg aripiprazole. 
Po rekonstituciji 1 ml suspenzije vsebuje 200 mg aripiprazola.
Aripiprazole may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls. 
Aripiprazol lahko povzroči somnolenco, posturalno hipotenzijo, motorično in senzorično nestabilnost,
h) If the injection is not performed immediately after reconstitution, keep the vial below 25 °C for up to 4 hours and shake it vigorously for at least 60 seconds to re-suspend prior to injection. 
h) Če zdravila ne injicirate takoj po rekonstituciji, vialo hranite pri temperaturi do 25 °C največ štiri ure in jo pred injiciranjem močno stresajte vsaj 60 sekund, da ponovno suspendira.
In a clinical trial of oral aripiprazole in healthy subjects, a strong inhibitor of CYP2D6 (quinidine) increased aripiprazole AUC by 107 %, while Cmax was unchanged. 
V kliničnem preskušanju peroralnega aripiprazola pri zdravih preiskovancih je močan zaviralec CYP2D6 (kinidin) zvečal AUC aripiprazola za 107 %, njegova Cmax pa se ni spremenila.
Developmental toxicity, including dose-dependent delayed foetal ossification and possible teratogenic effects, were observed in rats at doses resulting in sub-therapeutic exposures (based on AUC) and in rabbits at doses resulting in exposures approximately 3 and 11 times the mean steady-state AUC at the maximum recommended clinical dose. 
Razvojne toksične učinke, vključno z zapoznelo fetalno osifikacijo, odvisno od odmerka, in mogočimi teratogenimi učinki, so pri podganah opažali v odmerkih, ki so povzročili subterapevtsko izpostavljenost (na podlagi AUC), in pri kuncih v odmerkih, ki so povzročili izpostavljenost 3- in 11
Abilify Maintena with alcohol 
Zdravilo Abilify Maintena skupaj z alkoholom
Subjects with akathisia typically received anti-cholinergic medicines as treatment, primarily benzatropine mesilate and trihexyphenidyl. 
Preiskovanci z akatizijo so bili običajno zdravljeni z antiholinergičnimi zdravili, predvsem z benzatropin mesilatom in triheksifenidilom.